The POSTIVE (Pre-Operative STatin InterVEntion) study

The POSTIVE (Pre-Operative STatin InterVEntion) study - POSITIVE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34896

Enrollment

Registered

2010-06-25

Start date

2011-01-03

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial ischemia reperfusion injury

Interventions

simvastatin 40mg group 1: one dose of 40mg the evening before, and one dose of 40mg the morning of the operation group 2: one dose of 40mg a day starting a minimum of 14 days before the operation

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: open mitral and/or tricuspid valve surgery

Exclusion criteria

Exclusion criteria: • Statine use • Acceptation for minimal invasive mitral valve surgery • Inability to sign informed consent • Less than 18 years old • Ablation procedures • Emergency operations • Clinically diagnosed heart failure • Clinically diagnosed atherosclerosis • CABG procedures • Use of corticosteroids (e.g. prednisone etc.)

Design outcomes

Primary

Measure	Time frame
CRP, IL-6, ICAM1, vWF, cytokines, p-selectin, CK, troponins	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)